



FOR IMMEDIATE RELEASE

March 15<sup>th</sup>, 2022

**Anwita Biosciences, Inc. Announces Upcoming Late-Breaking Poster Presentation on the Preclinical Development of Mableukine-2PD1 at AACR Annual Meeting 2022**

SAN CARLOS, California, March 15<sup>th</sup>, 2022 – Anwita Biosciences, Inc. (“Anwita”), a clinical-stage biopharmaceutical company developing proprietary optimized cytokine-based therapeutics for cancer patients, announced the upcoming publication of a late-breaking presentation on Mableukine-2PD1 at the American Association of Cancer Research (AACR) Annual Meeting. Mableukine-2PD1, which is composed of an anti-PD-1 monoclonal antibody and a potency optimized no- $\alpha$  IL-2, is a highly safe and potent bifunctional fusion product capable of selectively expanding T cells within the tumor microenvironment without activating systemic toxicity. The AACR meeting will take place on April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

Details for the abstract and poster presentation are as follows:

Abstract Number: LB218  
Title: A safe and highly potent anti-PD-1-IL-2c fusion that decouples efficacy and toxicity of IL-2 therapy  
Session Title: Late-Breaking Research Immunology 2  
Session Data and Time: Wednesday Apr 13, 2022, 9:00 AM - 12:30 PM  
Location: Exhibit Halls D-H, Poster Section 18

The poster of the above abstract is expected to be released online at 1:00 PM ET on Friday, April 8<sup>th</sup> as per AACR guidance.

**About Anwita Biosciences, Inc.**

Anwita Biosciences, Inc. is an emerging biopharmaceutical company headquartered in the San Francisco Bay Area. Our mission is to deliver transformative treatment options to improve the lives of patients with cancer and autoimmune diseases. Anwita specializes in the discovery and development of optimized immunotherapeutics, leveraging its core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering.

**Investor Relations**

Contact: Investor Relations  
Telephone: (650) 600-9828  
Email: [contact@anwitabio.com](mailto:contact@anwitabio.com)  
Website: [www.anwitabio.com](http://www.anwitabio.com)